Difference between revisions of "Peginterferon alfa-2b (Sylatron)"
m |
m |
||
Line 1: | Line 1: | ||
+ | Also known as Sylatron. | ||
+ | |||
==General information== | ==General information== | ||
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/peginterferonalfa-2b.pdf Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)]</ref> | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to [[Interferon alfa-2b (Intron-A)]].<ref name="insert">[http://www.spfiles.com/pipeg-intron.pdf Peginterferon alfa-2b (PegIntron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/peginterferonalfa-2b.pdf Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)]</ref> | ||
Line 4: | Line 6: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== |
Revision as of 00:12, 29 February 2012
Also known as Sylatron.
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to Interferon alfa-2b (Intron-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Peginterferon alfa-2b (PegIntron) patient drug information (Chemocare)[3]
- Peginterferon alfa-2b (PegIntron) patient drug information (UpToDate)[4]